Parsippany, N.J., Jan. 7, 2026 /PRNewswire/ — Dexcel Pharma USA is excited to announce the successful closing of an Asset Purchase Agreement with Orexo AB to acquireParsippany, N.J., Jan. 7, 2026 /PRNewswire/ — Dexcel Pharma USA is excited to announce the successful closing of an Asset Purchase Agreement with Orexo AB to acquire

Dexcel Pharma USA Acquires US Rights to Zubsolv®

Parsippany, N.J., Jan. 7, 2026 /PRNewswire/ — Dexcel Pharma USA is excited to announce the successful closing of an Asset Purchase Agreement with Orexo AB to acquire the U.S. rights to Zubsolv® (buprenorphine and naloxone) sublingual tablets and the associated commercial infrastructure. This acquisition is an important milestone in the Company’s history, as it provides us with new capabilities to promote branded products.

Our CEO, Doug Boothe, added: “Dexcel Pharma is excited to be adding the Zubsolv® product and related commercial capabilities from Orexo into our expanding US operations. This product, together with our proven sales & marketing platform, will enable Dexcel Pharma’s strategic growth in the U.S.”

The Company thanks its employees and third-party advisors, including DLA Piper LLP (US) for their hard work and support in connection with this transaction. We look forward to working with new and existing customers and partners to ensure continued access to this important therapy in the treatment of opioid use disorder.

For more information please visit www.dexcelpharmausa.com

About Dexcel Pharma USA

Dexcel Pharma USA is the U.S. subsidiary of Dexcel Pharma. Dexcel Pharma is the largest private pharmaceutical company in Israel, commercializing an extensive portfolio of branded and generic drugs. Our state-of-the-art R&D and manufacturing facilities enable us to develop and manufacture high-quality products while maintaining long-term partnerships across the value chain.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/dexcel-pharma-usa-acquires-us-rights-to-zubsolv-302655715.html

SOURCE Dexcel Pharma USA

Market Opportunity
American Coin Logo
American Coin Price(USA)
$0.0000003241
$0.0000003241$0.0000003241
-2.40%
USD
American Coin (USA) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Real Estate Tokenization: Why Legal Architecture Matters More Than Technology

Real Estate Tokenization: Why Legal Architecture Matters More Than Technology

Oleg Lebedev on How Corporate Law Determines the Success or Failure of Digital Asset Projects. Real estate tokenization is gaining momentum worldwide.Visit Website
Share
Coinstats2026/01/10 02:00
Fed Makes First Rate Cut of the Year, Lowers Rates by 25 Bps

Fed Makes First Rate Cut of the Year, Lowers Rates by 25 Bps

The post Fed Makes First Rate Cut of the Year, Lowers Rates by 25 Bps appeared on BitcoinEthereumNews.com. The Federal Reserve has made its first Fed rate cut this year following today’s FOMC meeting, lowering interest rates by 25 basis points (bps). This comes in line with expectations, while the crypto market awaits Fed Chair Jerome Powell’s speech for guidance on the committee’s stance moving forward. FOMC Makes First Fed Rate Cut This Year With 25 Bps Cut In a press release, the committee announced that it has decided to lower the target range for the federal funds rate by 25 bps from between 4.25% and 4.5% to 4% and 4.25%. This comes in line with expectations as market participants were pricing in a 25 bps cut, as against a 50 bps cut. This marks the first Fed rate cut this year, with the last cut before this coming last year in December. Notably, the Fed also made the first cut last year in September, although it was a 50 bps cut back then. All Fed officials voted in favor of a 25 bps cut except Stephen Miran, who dissented in favor of a 50 bps cut. This rate cut decision comes amid concerns that the labor market may be softening, with recent U.S. jobs data pointing to a weak labor market. The committee noted in the release that job gains have slowed, and that the unemployment rate has edged up but remains low. They added that inflation has moved up and remains somewhat elevated. Fed Chair Jerome Powell had also already signaled at the Jackson Hole Conference that they were likely to lower interest rates with the downside risk in the labor market rising. The committee reiterated this in the release that downside risks to employment have risen. Before the Fed rate cut decision, experts weighed in on whether the FOMC should make a 25 bps cut or…
Share
BitcoinEthereumNews2025/09/18 04:36
Why Altcoins Could Be Primed for 5–10x Gains After Years of Consolidation

Why Altcoins Could Be Primed for 5–10x Gains After Years of Consolidation

Altcoins are poised for a potential 5-10x surge after long consolidation, with dominance set to rise in 2025 based on historical trends. The cryptocurrency market
Share
LiveBitcoinNews2026/01/10 02:32